Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menstrual Flow Excessive Clear all
Completed Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease

NCT06064851
View directory record Official record
Conditions
Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Interventions
Volta System
Device
Lead sponsor
Five Liters, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 22, 2026, 4:19 PM EDT
Recruiting Not applicable Interventional

Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms

NCT07084714
View directory record Official record
Conditions
Premenstrual Syndrome, Menstrual Cycle, Menstrual Distress (Dysmenorrhea), Menstrual Bleeding, Heavy
Interventions
Moderate Aerobic Exercise
Behavioral
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 22, 2026, 4:19 PM EDT
Withdrawn Phase 4 Interventional

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

NCT03325868
View directory record Official record
Conditions
Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 22, 2026, 4:19 PM EDT
Recruiting No phase listed Observational

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

NCT05922657
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions
Cerene
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 22, 2026, 4:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

HMB- Data Collection Methods

NCT02001324
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Web-based data collection, Paper-based data collection
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 22, 2026, 4:19 PM EDT
Recruiting Not applicable Interventional

Delivering tAN to Reduce HMB: The LUNA Study

NCT07326722
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Sparrow Link, Sparrow Link (Sham)
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of XP12B in Women With Menorrhagia

NCT00401193
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets, Placebo tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 22, 2026, 4:19 PM EDT
Withdrawn No phase listed Observational

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

NCT06058728
View directory record Official record
Conditions
Uterine Fibroids (UF)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 22, 2026, 4:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

NCT01581905
View directory record Official record
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness

NCT04267562
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding, Heavy Uterine Bleeding
Interventions
Minitouch System
Device
Lead sponsor
MicroCube, LLC
Industry
Eligibility
30 Years to 50 Years · Female only
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
5
States / cities
Newburgh, Indiana • Mason, Ohio • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 22, 2026, 4:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

NCT03704454
View directory record Official record
Conditions
Climacteric; Menorrhagia, Menopausal, Menopause
Interventions
50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC
Dietary Supplement
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

NCT02227316
View directory record Official record
Conditions
Symptomatic Uterine Fibroids and Adenomyosis
Interventions
IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 22, 2026, 4:19 PM EDT
Terminated Phase 3 Interventional Results available

Minimize Menorrhagia in Women With Von Willebrand Disease

NCT02606045
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
recombinant von Willebrand factor, tranexamic acid
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 22, 2026, 4:19 PM EDT
Recruiting No phase listed Observational

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

NCT05916469
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 22, 2026, 4:19 PM EDT
Completed No phase listed Observational

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

NCT03744507
View directory record Official record
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

NCT02829957
View directory record Official record
Conditions
Venous Thromboembolism, Menstruation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 22, 2026, 4:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 22, 2026, 4:19 PM EDT
Not yet recruiting Phase 4 Interventional

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

NCT07664956
View directory record Official record
Conditions
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions
Cyclobenzaprine
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 22, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03412890
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
104
States / cities
Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 22, 2026, 4:19 PM EDT